Acquisition Upsell ReachBio has been acquired by Discovery Life Sciences, expanding its cell biology capabilities and resources. This creates opportunities to engage Discovery’s broader client base in hematopoietic and primary cell assays, offering integrated services and cross-sell potential.

Hematopoietic Expertise Specialized focus on hematopoietic primary cell systems and toxicology, assay development, and biomarker strategies positions ReachBio to address drug screening and safety assessment needs for hematology-focused programs and developers seeking predictive toxicology data.

Platform Offerings Established platforms such as cellPrism, flow cytometry, biomarker selection, and drug screening capabilities can be packaged into tiered service offerings for partner CROs, pharma sponsors, and biotech firms pursuing translational hematology research.

Strategic Fit With a small headcount and revenue under one million, ReachBio presents an attractive integration point for larger CROs to augment their capabilities, particularly in primary cell biology, thrombocytopenia risk assessment, and predictive hematotoxicity services.

Market Expansion Discovery Life Sciences integration opens access to a broader customer network and cross-sell opportunities in biospecimens and biomarkers, enabling joint marketing initiatives and bundled offerings that appeal to drug development programs seeking comprehensive life-science solutions.